The prevalence of ASD in children and adults is around 1% of the population in the UK. There is an increasing understanding that ASD is a lifelong condition in which the core features persist whilst manifesting differently according to different age stages.
Remit and target users
This guideline updates SIGN 98, published in 2007 to reflect the most recent evidence covering children and young people. The guideline provides recommendations for best practice in the screening, surveillance, diagnosis, assessment and clinical interventions for children and young people with ASD. It also incorporates evidence and recommendations on assessment, diagnosis and interventions for adults with ASD.
This guideline will be of interest to healthcare professionals and other multiagency colleagues who work with children and adults with ASD, as well as people with ASD, their parents, carers, relatives, partners and others with whom they interact.
How this guideline was developed
This guideline was developed using a standard methodology based on a systematic review of the evidence. Further details can be found in SIGN 50: A Guideline Developer’s Handbook .
Keeping up to date
This guideline was issued in 2016 and will be considered for review in three years. The review history, and any updates to the guideline in the interim period, will be noted in the review report.
Current < 3 years
Full guideline (PDF)
Quick reference guide (PDF)
Declarations of interest (PDF)
Search narrative (PDF)
Review report (PDF)
Copyright permission (PDF)
Contact us email@example.com
SIGN 145, June 2016
ISBN 978 1 905813 46 7